3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Poly (ADP-Ribose) Polymerase Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1), supplied by APExBIO, is a selective inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC50 of ~50 nM in CHO cells, allowing for robust inhibition of PARP activity in cellular models (APExBIO product page). It achieves >95% inhibition of PARP at concentrations >1 μM without significant cytotoxicity, supporting its use in studies of oxidative stress and DNA repair. In vivo, 3-Aminobenzamide ameliorates diabetes-induced kidney dysfunction in db/db mice, reducing albumin excretion and podocyte loss. The compound's solubility and stability parameters make it suitable for diverse laboratory workflows. Its mechanistic specificity and reproducibility position it as a gold-standard tool for dissecting PARP-related pathways (Grunewald et al., 2019).

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze ADP-ribosylation, a post-translational modification essential for DNA repair, genomic stability, and cellular stress responses (Grunewald et al., 2019). Humans express at least 17 PARPs, with PARP1 and PARP2 predominantly responsible for poly (ADP-ribose) synthesis in response to DNA strand breaks. PARP activity consumes NAD+, linking metabolic status to DNA repair capacity. Excessive PARP activation, such as during oxidative or nitrosative stress, can deplete cellular NAD+ and ATP, leading to cell dysfunction or death. Inhibition of PARP has emerged as a strategy to modulate these pathways, providing therapeutic potential in ischemia-reperfusion injury, neurodegeneration, cancer, and diabetic complications. 3-Aminobenzamide (PARP-IN-1) enables experimental control over PARP-mediated ADP-ribosylation, facilitating both mechanistic and translational research.

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide (PARP-IN-1) acts as a competitive inhibitor at the nicotinamide binding site of PARP enzymes. This prevents the transfer of ADP-ribose moieties from NAD+ to target proteins, thereby blocking poly (ADP-ribosyl)ation events. Its molecular weight is 136.15 Da, with a chemical formula of C7H8N2O (APExBIO). The compound is cell-permeable and reaches effective concentrations in both in vitro and in vivo models. In Chinese Hamster Ovary (CHO) cells, its IC50 for PARP inhibition is approximately 50 nM, and >95% inhibition is observed at >1 μM without notable toxicity. By inhibiting PARP, 3-Aminobenzamide reduces NAD+ consumption, stabilizes ATP levels, and prevents cell death under oxidative stress conditions. This direct inhibition of PARP1 and related isoforms makes it a precise tool for dissecting the role of ADP-ribosylation in cellular biology and disease models.

Evidence & Benchmarks

• 3-Aminobenzamide inhibits PARP activity in CHO cells with an IC50 of ~50 nM, demonstrating high potency for poly (ADP-ribose) polymerase inhibition (APExBIO).
• At concentrations >1 μM, 3-Aminobenzamide achieves >95% inhibition of PARP activity without significant cytotoxic effects in cell-based assays (Grunewald et al., 2019).
• In diabetic db/db (Lepr db/db) mouse models, 3-Aminobenzamide reduces albuminuria, attenuates mesangial expansion, and preserves podocyte numbers, suggesting a renoprotective effect (APExBIO).
• PARP inhibition by 3-Aminobenzamide enhances acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation after hydrogen peroxide exposure, supporting vascular function studies (PrecisionFDA.org).
• In primary macrophages infected with coronaviruses, pan-PARP inhibitors including 3-Aminobenzamide enhance viral replication and suppress interferon production, validating its mechanistic specificity (Grunewald et al., 2019).
• For solution preparation, 3-Aminobenzamide is soluble in water (≥23.45 mg/mL), ethanol (≥48.1 mg/mL), and DMSO (≥7.35 mg/mL) with ultrasonic assistance, ensuring compatibility with diverse workflows (APExBIO).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in the following research contexts:

• PARP Activity Inhibition Assays: Enables quantitative measurement of PARP inhibition in live cells and lysates.
• Oxidant-Induced Myocyte Dysfunction: Used to model reperfusion injury and test interventions in cardiovascular studies.
• Endothelium-Dependent Vasorelaxation: Assesses nitric oxide-mediated vascular responses after oxidative stress.
• Diabetic Nephropathy Research: Studies the impact of PARP inhibition on kidney injury, albuminuria, and podocyte loss in diabetic models.
• Viral Pathogenesis Models: Used to dissect the role of PARPs in antiviral defense and interferon regulation (Grunewald et al., 2019).

This article provides new benchmarks and mechanistic clarity compared to this review, which focuses on immunometabolism and broader disease links, and this detailed protocol guide, which emphasizes assay optimization. This page consolidates the latest evidence on selectivity, in vivo performance, and mechanistic boundaries.

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not selective for individual PARP isoforms; it is considered a pan-PARP inhibitor.
• It is not suitable for clinical or diagnostic use; research use only as specified by APExBIO (product details).
• Long-term storage of solutions is not recommended; stability is optimal at -20°C for the dry compound.
• 3-Aminobenzamide does not inhibit extracellular ADP-ribosyltransferases (ARTCs) or sirtuins with high specificity.
• At supraphysiological concentrations, off-target effects may occur; always benchmark dose-response in each experimental system.

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) integrates efficiently into assays measuring cell viability, DNA repair, oxidative stress, and diabetic nephropathy endpoints. For CHO cell PARP inhibition, 50 nM is sufficient for IC50 determination, while 1 μM achieves nearly complete inhibition. Solubility is robust in water (≥23.45 mg/mL), ethanol (≥48.1 mg/mL), and DMSO (≥7.35 mg/mL) using ultrasonic assistance (APExBIO). Prepare fresh solutions before use; avoid long-term storage of aliquots. Shipping is performed on Blue Ice to preserve compound integrity. For more detailed workflow protocols and troubleshooting, see this protocol-driven analysis, which this article updates by incorporating newly published in vivo performance data.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a gold-standard tool for dissecting poly (ADP-ribose) polymerase biology in both in vitro and in vivo settings. Its well-characterized potency, favorable solubility, and robust mechanistic specificity support its continued use in studies of DNA repair, oxidative injury, and diabetic nephropathy. Future research may refine isoform selectivity or explore synergistic combinations with other inhibitors. For detailed product information and ordering, visit the APExBIO 3-Aminobenzamide (PARP-IN-1) product page.